We think differently to help our clients achieve success
| Medicare Part D |
|
The Medicare drug benefit exceeded all expectations in its first year to lower costs for beneficiaries and tax payers alike, while also increasing utilization and net price for manufacturers. But despite the program’s early success, uncertainties abound in the medium term for pharmaceutical manufacturers. |
| The global emerging biosimilar phenomenon – a forward-thinking P&R perspective |
|
Having crossed the $50 billion global sales threshold in 2005 and the $60 billion mark in 2006, it is no surprise that biologics represent one of the fastest growing fields in the pharmaceutical industry, making up a striking 30%+ share of drug pipelines. |
| Consumerism and the Rise of the Patient as Payer |
| We hear a lot these days about empowered patients and the rise in healthcare consumerism. The idea is that better informed patients, armed with unlimited information from the internet, are taking charge of their own health destiny in a new model of consumer-centric care. |
| Managing Parallel Trade Without Compromising Price |
| Increasing cross-border and in-market trading have complicated pharmaceutical trade flows in Europe, challenging drug integrity and compromising product sales. As the search for effective coping strategies intensifies, we consider why managing supply not minimizing price is the key to meeting the challenges of parallel trade. |
| Asian Free Trade Agreement (AFTA): No Change to Pricing & Reimbursement |
| ASEAN (Association of South East Asian Nations) 4 in its first 20 years failed to bring about greater regional economic integration. The ongoing implementation of an ASEAN Free Trade Area (AFTA) has succeeded in reducing tariffs, but non-tariff barriers remain in force. We do not expect AFTA to have a significant impact on pharmaceutical pricing and reimbursement, manufacturing, and trading strategy in Asia. |
| The Future of Price Regulation in the U.S. Pharmaceutical Market |
| Over the past few years, the battleground on pharmaceutical prices in the US has focused on importation - a highly emotional issue for both consumers and politicians. The debate over importation has rightly attracted the attention of the pharmaceutical industry because of its potentially damaging financial implications. |
| NICE– where are we now? |
| When the National Institute for Clinical Excellence (NICE) was set up in 1999, it looked like a rationing body. However its recommendations have been largely positive, and attention has shifted to the British problem of slow uptake. |
| Medicaid |
| Pharma/biotech companies should manage Medicaid like their managed care businesses. |
| Are you prepared for EU Enlargement? |
| There is a distinct possibility that European revenues and profits will be diluted by the impact of EU enlargement next year! |